One Vertex Insider Raised Stake By 25% In Previous Year

Insiders were net buyers of Vertex, Inc.'s ( NASDAQ:VERX ) stock during the past year. That is, insiders bought ...

Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference ...
FiercePharma

Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...

Vertex's gene therapy shows promise in younger children with blood disorders

Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease ...
The Motley Fool

Vertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy

Just last week, I wrote why you'd be smart to buy Vertex Pharmaceuticals (VRTX-0.63%) stock. At that time, Vertex was up around 70% for the year. My argument then was that the stock was still ...